No additional charge on stents as rates include 8% margin, says govt
- Lodha Group aims to reduce debt by more than Rs1,000 crore this fiscal
- National interest first, politics comes later
- Liberty House moves NCLT against rejection of Bhushan Power bid
- I personally feel NHPS has not been thought through fully: Kiran Mazumdar-Shaw
- December quarter data likely to show pick-up in GDP growth
New Delhi: As trade margin of 8% is included in the ceiling price of stents, no additional charge except local sales taxes and value added tax (VAT) can be demanded from the patients, the government said on Monday.
“It is pertinent to mention that 8% maximum margin has been built into the calculation of the ceiling price of the coronary stents”, National Pharmaceutical Pricing Authority (NPPA) said in a memorandum on its website.
No additional charge whatsoever, over and above the ceiling price notified in the price notification of 13 February 2017, shall be charged from the consumer except local sale taxes/VAT, if paid in actual, it added.
“Considering the high end value market of the coronary stents, this 8% trade margin would cover margins across the trade channels working from the level of manufacturer/importer to end user i.e. consumers/patient,” the regulator said.
The 8% margin also adequately covers hospital handling charges, if any, it added.
In a major relief to patients, the government had slashed prices of coronary stents by up to 85%, capping them at Rs7,260 for bare metal ones and Rs29,600 for the drug eluting variety.
The maximum retail price of bare metal stents (BMS) and drug eluting stents (DES) will be Rs7,623 and Rs31,080, respectively, inclusive of VAT and other local taxes, chemical and fertilizer minister Ananth Kumar had said. A coronary stent is a tube-shaped device placed in the arteries that supply blood to the heart. It keeps the arteries open in the treatment of coronary heart diseases.